We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Best of the Best |

Top-Accessed Article: Notalgia Paresthetica Treated With Botulinum Toxin Type A FREE

Gil Yosipovitch, MD
Arch Dermatol. 2010;146(11):1299. doi:10.1001/archdermatol.2010.285.
Text Size: A A A
Published online

Weinfeld PK. Successful treatment of notalgia paresthetica with botulinum toxin type A. Arch Dermatol.2007;143(8):980-982.

Notalgia paresthetica is a form of entrapment neuropathy involving the posterior rami of spinal nerves T2 to T6. In a few cases, it is resistant to conventional therapies, and the itch significantly impairs the patient's quality of life. Weinfeld reported using a novel treatment consisting of botulinium toxin type A in doses ranging from 16 to 48 U in 2 patients with persistent notalgia paresthetica. Four units of the toxin were injected intradermally in several points along the involved dermatomes. Interestingly, in both cases, its effect for this condition lasted longer than its effect for muscular contractions and glandular secretions. The rationale for the use of botulinum toxin type A is that it inhibits the release of acetylcholine and neuropeptides such as substance P and glutamate, which are involved in neuropathic itch. This anecdotal report holds promise as a novel approach to the treatment of other forms of neuropathic itch.

From June 2004 through August 2009, this article was viewed 2866 times on the Archives of Dermatology Web site.


Contact Dr Yosipovitch at the Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 (gyosipov@wfubmc.edu)





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.